Biohaven Ltd. and SK Biopharmaceuticals Co., Ltd. have executed a global licensing agreement covering the rights to Biohaven's epilepsy portfolio. Under the arrangement, Biohaven grants SK Biopharmaceuticals the rights to develop and commercialize the epilepsy drug opakalim as well as access to its Kv7 epilepsy platform across international markets. The financial consideration for the transaction is set at $795 million, establishing a major commercial framework for the advancement of these neurological assets.
The agreement positions SK Biopharmaceuticals as the primary partner tasked with global execution for the licensed indications. Through this global licensing deal, SK Biopharmaceuticals secures broad control over the future trajectory of the platform, encompassing ongoing research, regulatory pathways, and market deployment. For Biohaven, identified by ticker symbol BHVN, the $795 million valuation represents a significant capital event tied to the intellectual property transfer. SK Biopharmaceuticals, traded as 326030.KS, acquires the ability to integrate the Kv7 technology and opakalim into its existing corporate operations on a worldwide basis.
Stock markets responded positively to the announcement of the partnership. Shares of Biohaven climbed by 13% upon the release of the deal details, signaling strong market validation of the financial terms and the strategic utility of the licensing model. Concurrently, the stock of SK Biopharmaceuticals saw substantial gains, driven by investor enthusiasm surrounding the acquisition of the proprietary epilepsy assets. The simultaneous movement in both equities highlights the perceived mutual benefit of the $795 million commitment and the potential for the Kv7 platform to deliver value.
Central to the agreement is the Kv7 epilepsy platform, which comprises Biohaven's technology focused on addressing seizure-related disorders. Opakalim stands as a key therapeutic agent within this scope, slated for advancement under the terms of the new arrangement. The global nature of the license ensures that development efforts and commercialization initiatives will proceed across multiple regions simultaneously. Both entities are expected to contribute resources toward the progression of the drug candidates, leveraging Biohaven's discovery capabilities in conjunction with SK Biopharmaceuticals' operational reach to pursue regulatory approvals and patient access globally.